Running Point Capital Advisors’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Running Point Capital Advisors’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000	Closed	-$5K	–	235
2022 Q3	$5K	Sell	1,000 -70	-7%	-$390	﹤0.01%	207
2022 Q2	$6K	Hold	1,070	–	–	﹤0.01%	212
2022 Q1	$8K	Buy	+1,070	New	+$10.5K	﹤0.01%	203

Other funds holding ORTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Running Point Capital Advisors's ORTX Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2022, closing a stake of 1,000 shares — an estimated $5K sold.

Running Point Capital Advisors first reported a position in ORTX in Q1 2022 and held it in 3 quarters. The position peaked at $8K in Q1 2022. 47 funds tracked by Wall St. Rank hold ORTX as of Q4 2022.

Running Point Capital Advisors reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2022 after selling out during the quarter.
Running Point Capital Advisors sold 1,000 Orchard Therapeutics plc American Depositary Shares shares in Q4 2022, an estimated $5K.
Running Point Capital Advisors first reported a position in Orchard Therapeutics plc American Depositary Shares in Q1 2022 and held it in 3 quarters.
Running Point Capital Advisors's Orchard Therapeutics plc American Depositary Shares position peaked at $8K in Q1 2022.
47 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.